SHIKARI® Eculizumab ELISA (Q-ECU)

This kit has been especially developed for the quantitative determination of eculizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work. All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

Please contact us at for specific academic pricing.

Background

Eculizumab Drug Bank Accession Number is DB01257

Eculizumab is a recombinant humanized monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. By the inhibition of this complex, eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce the risk of complement mediated intravascular hemolysis, to prevent complement mediated microangiopathy in atypical hemolytic uremic syndrome and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder (NMOSD).

More Details